drugset / Trial / NCT06944717
A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old
Non-randomizedSequentialOpen-labelPrevention
Summary
The primary objective of this study is to determine the safety and immunogenicity of low and high dose regimens of a next generation norovirus bivalent G1.1 and G2.4 vaccine candidate in healthy participants.
Timeline
- Start
- 2025-03-03
- Primary completion
- 2026-05-01
- Completion
- 2026-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VXA G1.1 NN-T | Vaccine | 1e+10 iu | Oral |
| Subject | VXA G1.1 NN-T | Vaccine | 1e+11 iu | Oral |
| Subject | VXA G2.4 NS-T | Vaccine | 1e+10 iu | Oral |
| Subject | VXA G2.4 NS-T | Vaccine | 1e+11 iu | Oral |
| Subject | VXA-G1.1-NN | Vaccine | 1e+11 iu | Oral |
| Subject | VXA-G2.4-NS | Vaccine | 1e+11 iu | Oral |